UNITED
      STATES


SECURITIES
      AND EXCHANGE COMMISSION


Washington,
      D.C. 20549





FORM
      10-Q





(Mark
      One)


þ
            Quarterly
                Report Under Section 13 or 15(d) of the Securities Exchange Act of
                1934For
                the quarterly period ended June 30, 2008o
            Transition
                Report Under Section 13 or 15(d) of the Securities Exchange Act of
                1934For
                the transition period fromto





Commission
      File Number 000-03125





ADUROMED
      INDUSTRIES, INC.


(Exact
      Name of Registrant as Specified in Its Charter)





Delaware      21-0661726


(State
      or
      other Jurisdiction of    (I.R.S.
      Employer


incorporation
      or organization)    Identification
      Number)




3
      Trowbridge Drive


Bethel,
      Connecticut 06801


(Address
      of Principal Executive offices)





(203)
      798-1080


(Issuer’s
      Telephone Number)





Indicate
      by check mark whether the registrant: (1) has filed all reports required to
      be
      filed by Section


13
      or
      15(d) of the Exchange Act during the preceding 12 months (or for such
      shorter


period
      that the registrant was required to file such reports), and (2) has
      been


subject
      to such filing requirements for the past 90 days.


Yes þ No o





Indicate
      by check mark whether the registrant is a large accelerated filer, an
      accelerated filer, or a non-accelerated filer. See definition of “accelerated
      filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check
      one):





Large
                Accelerated Filero
            
            Accelerated
                FileroNon-Accelerated
                Filero
            
            Smaller
                Reporting Companyþ





Indicate
      by check mark whether the registrant is a shell company (as defined
      in


Rule
      12b-2 of the Exchange Act). Yes o No þ





As
      of
      August 8, 2008 455,593,581 shares of the issuer’s common stock (par value
      $0.0001 per share) were outstanding.





TABLE
      OF
      CONTENTS








PART
      I--FINANCIAL INFORMATION


PageItem
                  1:Financial Statements
              F1
                  - F12Item
                  2:Management's Discussion and Analysis or Plan of
                  Operation
              3Item
                  3: Quantitative and Qualitative disclosures about Market
                  Risk
              7Item
                  4: Controls and Procedures
              7PART
                  II--OTHER INFORMATIONItem
                  1: Legal Proceedings
              8Item1A:
                  Risk Factors
              8Item
                  2: Unregistered Sales of Equity Securities and Use of
                  Proceeds
              8Item
                  3: Defaults Upon Senior Securities
              8Item
                  4: Submission of Matters to a Vote of Security Holders
              8Item
                  5: Other Information
              8Item
                  6: Exhibits
              9Signatures
              9












**PART
      I--FINANCIAL INFORMATION**





**Item
      1. Financial Statements** `








INDEX
      TO
      CONSOLIDATED FINANCIAL STATEMENTS








PAGECONDENSED
                CONSOLIDATED BALANCE SHEETS AS OF JUNE 30, 2008 AND DECEMBER 31,
                2007
            F2UNAUDITED
                CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE MONTHS
                ENDED
                JUNE 30, 2008 AND 2007
            F3UNAUDITED
                CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE SIX MONTHS
                ENDED
                JUNE 30, 2008 AND 2007
              
              UNAUDITED
                CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE SIX MONTHS
                ENDED
                JUNE 30, 2008 AND 2007
            F4
              
              
              F5NOTES
                TO CONSOLIDATED FINANCIAL STATEMENTS
            F6







F-1


ADUROMED
        INDUSTRIES, INC.
 
 CONDENSED
        CONSOLIDATED BALANCE SHEETS


June
                  30,
              
              
              December
                  31,ASSETS
              
              
              2008
              
              
              2007(Unaudited)Current
                  assetsCash
              
              $
              71,575
              
              $
              212,215Accounts
                  receivable(net of $11,418 allowance)
              
              
              56,198
              
              
              739,840Revenues
                  in excess of billings
              
              
              55,535
              
              
              -Inventory
              
              
              631,098
              
              
              900,938Prepaid
                  expenses
              
              
              -
              
              
              55,350Total
                  current assets
              
              
              814,406
              
              
              1,908,343Property,
                  plant and equipment, net
              
              
              300,286
              
              
              351,179Long
                  term deposits
              
              
              17,988
              
              
              17,988Total
                  assets
              
              $
              1,132,680
              
              $
              2,277,510LIABILITIES
                  AND STOCKHOLDERS' DEFICITCurrent
                  liabilitiesAccounts
                  payable and accrued liabilities
              
              $
              826,844
              
              $
              517,402Deferred
                  revenue
              
              
              157,702
              
              
              245,391Dividends
                  payable
              
              
              1,074,013
              
              
              864,013Accrued
                  liquidated damages
              
              
              602,000
              
              
              602,000Billings
                  in excess of revenue
              
              
              853,141
              
              
              1,221,338Short
                  term secured notes payable
              
              
              1,225,000
              
              
              1,225,000Convertible
                  debt, face value $1,225,000, due August 4, 2008
              
              
              1,159,733
              
              
              28,892Short
                  term notes payable related party
              
              
              250,000
              
              
              -Current
                  portion of notes payable
              
              
              313,563
              
              
              197,756Total
                  current liabilities
              
              
              6,461,996
              
              
              4,901,792Notes
                  payable, less current portion
              
              
              -
              
              
              62,476Total
                  liabilities
              
              
              6,461,996
              
              
              4,964,268Stockholders'
                  deficitPreferred
                  stock:$.0001 par value; 60,000,000 shares authorized; 22,043,862 shares
                  issued
                  and outstanding
              
              
              2,204
              
              
              2,204Common
                  stock:$.0001
                  par value; 1,400,000,000 shares authorized; 21,890,306 and 21,665,306
                  shares issued and outstanding
              
              
              2,212
              
              
              2,167Additional
                  paid-in capital
              
              
              9,965,483
              
              
              9,363,671Accumulated
                  deficit
              
              
              (15,299,215
              )
              
              (12,054,800
              )Total
                  stockholders' deficit
              
              
              (5,329,316
              )
              
              (2,686,758
              )Total
                  liabilities and stockholders' deficit
              
              $
              1,132,680
              
              $
              2,277,510
  See
        Notes
        to Consolidated Financial Statements







F-2


ADUROMED
        INDUSTRIES, INC.
 
 CONDENSED
        CONSOLIDATED STATEMENTS OF OPERATIONS
 (Unaudited)








For
                  the Three Months EndedJune
                  30,2008
              
              
              2007RevenuesContract
                  revenues earned
              
              $
              330,739
              
              $
              532,657Sales
                  and service revenues
              
              
              187,216
              
              
              228,858Total
                  revenues
              
              
              517,955
              
              
              761,515Cost
                  of sales
              
              
              333,484
              
              
              408,910Gross
                  profit
              
              
              184,471
              
              
              352,605Operating
                  expensesSalaries
                  and wages
              
              
              319,149
              
              
              406,352General
                  and administrative expenses
              
              
              518,144
              
              
              440,605Depreciation
                  expense
              
              
              21,956
              
              
              23,382Total
                  operating expenses
              
              
              859,249
              
              
              870,339Loss
                  from operations
              
              
              (674,778
              )
              
              (517,734
              )Other
                  income and expensesInterest
                  income
              
              
              239
              
              
              4,840Interest
                  expense
              
              
              (836,081
              )
              
              (47,385
              )Total
                  other income and expenses
              
              
              (835,842
              )
              
              (42,545
              )Net
                  loss before income taxes
              
              
              (1,510,620
              )
              
              (560,279
              )Provision
                  for income tax benefit
              
              
              -
              
              
              -Net
                  loss
              
              $
              (1,510,620
              )
              $
              (560,279
              )Basic
                  and diluted net loss per common share
              
              $
              (0.07
              )
              $
              (0.03
              )Weighted
                  average common shares outstanding
              
              
              22,015,101
              
              
              20,683,257


See
        Notes
        to Consolidated Financial Statements





F-3


ADUROMED
        INDUSTRIES, INC.
 
 CONDENSED
        CONSOLIDATED STATEMENTS OF OPERATIONS
 (Unaudited)


For
                  the Six months endedJune
                  30,2008
              
              
              2007RevenuesContract
                  revenues earned
              
              $
              854,223
              
              $
              1,114,248Sales
                  and service revenues
              
              
              351,758
              
              
              417,873Total
                  revenues
              
              
              1,205,981
              
              
              1,532,121Cost
                  of sales
              
              
              809,082
              
              
              921,863Gross
                  profit
              
              
              396,899
              
              
              610,258Operating
                  expensesSalaries
                  and wages
              
              
              689,990
              
              
              822,944General
                  and administrative expenses
              
              
              1,083,691
              
              
              968,085Depreciation
                  expense
              
              
              44,315
              
              
              46,582Total
                  operating expenses
              
              
              1,817,996
              
              
              1,837,611Loss
                  from operations
              
              
              (1,421,097
              )
              
              (1,227,353
              )Other
                  income and expensesInterest
                  income
              
              
              614
              
              
              13,709Interest
                  expense
              
              
              (1,613,932
              )
              
              (93,313
              )Total
                  other income and expenses
              
              
              (1,613,318
              )
              
              (79,604
              )Net
                  loss before income taxes
              
              
              (3,034,415
              )
              
              (1,306,957
              )Provision
                  for income tax benefit
              
              
              -
              
              
              -Net
                  loss
              
              $
              (3,034,415
              )
              $
              (1,306,957
              )Basic
                  and diluted net loss per common share
              
              $
              (0.15
              )
              $
              (0.07
              )Weighted
                  average common shares outstanding
              
              
              21,895,940
              
              
              20,683,257







See
      Notes
      to Consolidated Financial Statements






F-4




ADUROMED
        INDUSTRIES, INC.
 
 CONDENSED
        CONSOLIDATED STATEMENTS OF CASH FLOWS
 (Unaudited)







Six
                months endedJune
                30,2008
            
            
            2007Cash
                flows from operating activities:Net
                loss
            
            $
            (3,034,415
            )
            $
            (1,306,957
            )Adjustments
                to reconcile net loss tonet
                cash used in operations:Stocks,
                Warrants and options issued for services
            
            
            601,857
            
            
            167,999Depreciation
                expense
            
            
            44,315
            
            
            46,582Disposal
                of Fixed Assets
            
            
            6,578
            
            
            -Changes
                in operating assets and liabilities:Accounts
                receivable
            
            
            683,642
            
            
            (381,097
            )Revenues
                in excess of billings
            
            
            (55,535
            )
            
            72,610Inventory
            
            
            269,840
            
            
            (130,499
            )Prepaid
                expenses
            
            
            55,350
            
            
            (153,462
            )Accounts
                payable and accrued liabilities
            
            
            99,442
            
            
            (787,665
            )Changes
                in convertible debt
            
            
            1,130,841
            
            
            -Deferred
                revenue
            
            
            (87,689
            )
            
            34,407Billings
                in excess of revenue
            
            
            (368,197
            )
            
            199,512Interest
                on notes payable
            
            
            5,850
            
            
            5,850Dividends
                payable
            
            
            210,000
            
            
            210,000Net
                cash used in operating activities
            
            
            (438,121
            )
            
            (2,022,720
            )Cash
                flows from investing activities:Purchase
                of fixed assets
            
            
            -
            
            
            (10,429
            )Net
                cash used in investing activities
            
            
            -
            
            
            (10,429
            )Cash
                flows from financing activities:Issuance
                of convertible notes
            
            
            
            
            
            1,275,000Repayments
                of notes payable
            
            
            (52,519
            )
            
            (3,927
            )Issuance
                of note payable
            
            
            300,000
            
            
            -Increase
                in line of credit
            
            
            50,000
            
            
            -Net
                cash provided by financing activities
            
            
            297,481
            
            
            1,271,073Decrease
                in cash and cash equivalents
            
            
            (140,640
            )
            
            (762,076
            )Cash
                and cash equivalents, beginning of period
            
            
            212,215
            
            
            1,892,336Cash
                and cash equivalents, end of period
            
            $
            71,575
            
            $
            1,130,260Supplemental
                disclosures of cash flow information:Cash
                paid for interest
            
            $
            77,131
            
            $
            2,968Supplemental
                disclosures of non-cash investing and financing
                activities:Accrual
                of preferred stock dividends
            
            $
            210,000
            
            $
            210,000




See
        Notes
        to Consolidated Financial Statements





F-5




1.  BASIS
      OF
      PRESENTATION





The
      condensed consolidated balance sheets of Aduromed Industries Inc., and
      subsidiaries (“Aduromed”, the “Company”, “AII”) as of June 30, 2008 and December
      31, 2007, the condensed consolidated statements of operations for the three
      and
      six month period ended June 30, 2008 and 2007, and the condensed consolidated
      statements of cash flows for the six month period ended June 30, 2008 and 2007
      have been prepared by the Company without audit. In the opinion of management,
      the information contained herein reflects all adjustments necessary to make
      the
      presentation of the Company’s condensed financial position, results of
      operations and cash flows not misleading. All such adjustments are of a normal
      recurring nature.





The
      accompanying condensed consolidated financial statements do not contain all
      of
      the information and disclosures required by accounting principles generally
      accepted in the United States of America and should be read in conjunction
      with
      the consolidated financial statements and related notes included in the
      Company’s annual report on Form 10-K for the fiscal year ended December 31,
      2007, filed on March 31, 2008 and amended on July 24, 2008.





The
      accompanying consolidated financial statements have been prepared assuming
      that
      the Company will continue as a going concern, which contemplates the realization
      of assets and satisfaction of liabilities and commitments in the normal course
      of business. The Company has incurred substantial recurring losses, which raises
      substantial doubt about its ability to continue as a going concern. The
      consolidated financial statements do not include any adjustments that might
      result from the outcome of this uncertainty.





The
      Company has available cash and cash equivalents of approximately $71,575 at
      June
      30, 2008 which it intends to utilize for working capital purposes and to
      continue developing its business. On August 4, 2008 the Company closed on a
      Master Restructuring Agreement (“MRA”) pursuant to which the Company has
      received $4,405,000 in equity funding as of the date of this filing and has
      retired or converted all of its preferred stock, liquidated damages, accrued
      dividends on the preferred stock and a bridge loan in the amount of $1,225,000
      into shares of common stock. Concurrent with the MRA, the Company increased
      its
      authorized common shares to 1.4 billion shares of common stock. With the
      restructuring agreement and $4,405,000 received in cash, the Company believes
      it
      has adequate cash for the next 12 months.








2.  BUSINESS
      DESCRIPTION - ORGANIZATION





The
      Company designs, fabricates and installs systems to treat regulated medical
      waste on site. Its principal products are the Aduromed MedClean® series systems.
      AII through its subsidiary provides MedClean® systems to hospitals and other
      medical facilities as efficient, safe, cost-effective and legally-compliant
      solutions as alternatives to incineration or off-site hauling of untreated
      medical waste and to other types of alternative treatment technologies and
      methodologies.










F-6







3.  SUMMARY
      OF SIGNIFICANT ACCOUNTING POLICIES





EARNINGS
      (LOSS) PER COMMON SHARE





The
      net
      earnings (loss) per common share are computed by dividing the net loss for
      the
      period by the weighted average number of shares outstanding for the period.
      Outstanding warrants and options for the period ending June 30, 2008 and 2007
      amounting to 43,943,271 and
      43,774,696 respectively were not included in the calculation for net loss per common share
      because it would be antidilutive.





Outstanding
      Preferred A and B class of stock nor the common stock equivalents associated
      with the conversion feature for the period ending June 30, 2008 and 2007
      amounting to 22,043,862 for both periods of both classes of Preferred stock
      were
      not included in the calculation for net loss per common share as it would be
      antidilutive.





The
      numerator and denominator used in the basic and diluted earnings (loss) per
      share of common stock computations are presented in the following
      table:







Six
                  months ended June 30,
              
              
              Three
                  months ended June 30,2008
              
              
              2007
              
              
              2008
              
              
              2007NUMERATOR
                  FOR BASIC AND DILUTED EPS (LPS)Net
                  loss per statement of operations
              
              $
              (3,034,415
              )
              $
              (1,306,957
              )
              $
              (1,510,620
              )
              $
              (560,279
              )Dividend
                  payable to preferred stockholders
              
              
              (210,000
              )
              
              (210,000
              )
              
              (105,000
              )
              
              (105,000
              )Net
                  loss to common stockholders
              
              $
              (3,244,415
              )
              $
              (1,516,957
              )
              $
              (1,615,620
              )
              $
              (665,279
              )DENOMINATOR
                  FOR BASIC AND DILUTED EPS (LPS)Weighted
                  average shares of common stock outstanding
              
              
              21,895,940
              
              
              20,683,257
              
              
              22,015,101
              
              
              20,683,257Basic
                  and diluted EPS (LPS)
              
              $
              (0.15
              )
              $
              (0.07
              )
              $
              (0.07
              )
              $
              (0.03
              )






USE
      OF
      ESTIMATES





The
      preparation of the accompanying financial statements, in conformity with
      generally accepted accounting principles, requires management to make estimates
      and assumptions that affect the reported amounts of assets and liabilities,
      and
      disclosure of contingent assets and liabilities at the date of the financial
      statements, and the reported amounts of revenue and expenses during the
      reporting periods. Actual results could differ from those
      estimates.





CASH
      AND
      CASH EQUIVALENTS





The
      Company considers all highly liquid debt instruments purchased with an original
      maturity of three months or less to be cash equivalents.





The
      Company maintains cash deposits with financial institutions, which from time
      to
      time may exceed federally insured limits. The Company has not experienced any
      losses and believes it is not exposed to any significant credit risk from cash.
      At June 30, 2008, the Company has no cash balances on deposit in any one account
      with a financial institution in excess of the federally insured limits.





CONTROL
      BY PRINCIPAL STOCKHOLDERS





The
      directors, executive officers, participants in the Master Restructuring
      Agreement and their affiliates or related parties, own beneficially and in
      the
      aggregate, the majority of the voting power of the outstanding shares
      of
      the common stock of the Company. Accordingly, the directors, executive officers
      and their affiliates, if they voted their shares uniformly, would
      have the ability to control the approval of most corporate actions, including
      increasing the authorized capital stock of the Company and the dissolution,
      merger or sale of the Company's assets.






F-7





DEPENDENCE
      ON PRINCIPAL CUSTOMER





One
      principal customer, Aramark, represents a significant portion of our revenues.
      We recognized revenue of approximately $420,050 or 35% and $424,974 or 28%
      of
      total revenue from Aramark in the six months ended June 30, 2008 and 2007,
      respectively. The loss of our principal customer would have a significant
      adverse impact on our business.





ACCOUNTS
      RECEIVABLE





The
      Company maintains an accounts receivable ledger to track amounts due from
      individual customers. The Company continuously monitors the creditworthiness
      of
      its customers and has established an allowance for amounts that may be
      uncollectible in the future based on current economic conditions, historical
      payments and specific customer related collection issues. The allowance for
      bad
      debts was $11,418 as of June 30, 2008 and December 31, 2007.





PROPERTY,
      PLANT AND EQUIPMENT





The
      Company has property, plant and equipment that consist of automobiles, computers
      and related accessories, and office furniture. The depreciation is calculated
      using the straight line method over the life of the property. All property
      has a
      useful life of 3 to 10 years. The following table summarizes these assets as
      of
      June 30, 2008 and December 31, 2007:




June
                  30,
              
              
              December
                  31,2008
              
              
              2007Vehicles
              
              
              31,061
              
              
              41,338Office
                  Furniture
              
              
              164,525
              
              
              164,525Computers
                  and Accessories
              
              
              167,081
              
              
              175,485Leasehold
                  Improvements
              
              
              117,997
              
              
              117,997480,664
              
              
              499,345Accumulated
                  Depreciation
              
              
              180,378
              
              
              148,166300,286
              
              
              351,179





INVENTORY





The
      Company maintains an inventory, which consists primarily of component parts,
      spare parts and disposable goods. The average cost method is utilized in valuing
      the inventory, and is stated at the lower of cost or market. The following
      table
      summarizes these assets as of June 30, 2008 and December 31, 2007:




June
                  30,
              
              
              December
                  31,2008
              
              
              2007Component
                  & spare parts
              
              
              146,858
              
              
              742,310Consumables
              
              
              20,446
              
              
              29,384Advance
                  payments
              
              
              132,982
              
              
              129,244Total
                  inventory
              
              
              300,286
              
              
              900,938





F-8




REVENUE
      RECOGNITION


The
      Company recognizes revenues from fixed-price and modified fixed-price
      construction type contracts on the percentage-of-completion method, measured
      by
      the percentage of cost incurred to date to estimated total cost for each
      contract. That method is used because management considers total cost to be
      the
      best available measure of progress on the contracts. Because of inherent
      uncertainties in estimating costs, it is at least reasonably possible that
      the
      estimates used will change within the near term. The Company typically bills
      25%
      of the contract at signing, 50% upon delivery of components, and the final
      25%
      upon completion of installation and start-up.





Contract
      costs include all direct material and labor costs and those indirect costs
      related to contract performance. Selling, general and administrative costs
      are
      charged to expense as incurred. Provisions for estimated losses on uncompleted
      contracts are made in the period in which such losses are determined. Changes
      in
      job performance, job conditions, and estimated profitability may result in
      revisions to costs and income, which are recognized in the period in which
      the
      revisions are determined. Changes in estimated job profitability resulting
      from
      job performance, job conditions, contract penalty provisions, claims, change
      orders, and settlements, are accounted for as changes in estimates in the
      current period.





The
      Company provides a one year warranty on the systems it installs. The Company
      also obtains a one year warranty on the system components from the component
      manufacturer, thereby mitigating potential warranty costs. Accordingly, the
      Company has accrued no reserve for warranty. After the warranty term expires
      the
      Company offers a maintenance agreement of one or more years to the customer.
      The
      Customer is billed for, and pays for the maintenance agreement in advance.
      Revenues from such maintenance agreements are recognized ratably over the lives
      of the maintenance agreements, with the excess of the amount collected over
      the
      amount recognized as deferred revenue. At June 30, 2008 and December 31, 2007,
      the Company had $157,702 and $245,391, respectively in deferred revenue from
      maintenance agreements.





Revenues
      from the sale of accessories, repairs and replacement parts are recognized
      when
      the goods are shipped to the customer in accordance with a valid order
      agreement. The order agreement specifies delivery terms and pricing, and is
      considered to reasonably assure collection from the customer.








4.  CONTRACTS
      IN PROGRESS





The
      Company entered into construction type contracts to furnish and install its
      systems in hospitals. There were six outstanding contracts at June 30, 2008.
      The
      following table summarizes these outstanding contracts:











F-9





Contract
              
              
              Revenue
              
              
              Amounts
              
              
              Revenues
                  in
              
              
              Billings
                  in excessAmount
              
              
              Recognized
              
              
              Billed
              
              
              excess
                  of Billings
              
              
              of
                  RevenuesOutstanding
                  contracts at June 30, 20081,327,930
              
              
              949,221
              
              
              1,327,930
              
              
              -
              
              
              378,709231,257
              
              
              12,447
              
              
              12,447
              
              
              -
              
              
              -483,596
              
              
              163,939
              
              
              215,271
              
              
              -
              
              
              51,332299,759
              
              
              64,875
              
              
              188,632
              
              
              -
              
              
              123,757559,594
              
              
              76,219
              
              
              375,562
              
              
              -
              
              
              299,343473,014
              
              
              370,877
              
              
              315,342
              
              
              55,535
              
              
              -55,535
              
              
              853,141Outstanding
                  contracts at December 31, 20071,327,930
              
              
              683,593
              
              
              1,327,930
              
              
              -
              
              
              644,337483,117
              
              
              458,995
              
              
              483,117
              
              
              -
              
              
              24,122231,257
              
              
              12,447
              
              
              12,447
              
              
              -
              
              
              -483,596
              
              
              106,076
              
              
              120,899
              
              
              -
              
              
              14,823257,820
              
              
              -
              
              
              257,820
              
              
              -
              
              
              257,820282,948
              
              
              -
              
              
              94,316
              
              
              -
              
              
              94,316559,594
              
              
              5,611
              
              
              191,531
              
              
              -
              
              
              185,920-
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              1,221,338





5.  SHORT-TERM
      NOTES PAYABLE RELATED PARTY





On
      March
      17, 2008, the Company entered into a factoring agreement with a stockholder
      of
      the Company whereby the Company received $300,000 secured by specific milestone
      billings. The company agreed to pay interest at 15% per annum. As further
      incentive the Company issued 600,000 warrants with an exercise price of $0.09. The
      estimated value of the warrants is added to paid-in-capital and amortized to
      interest expense over the live of the loan. The
      warrant agreement expires on March 16, 2013. On May 23 2008, the Company repaid
      $50,000 of principal on this note and on August 7, 2008, repaid the remaining
      balance of $250,000 with accrued interest of $16,200.





6.  NOTE
      PAYABLE





The
      Company has a note payable to a bank. The note is personally guaranteed by
      an
      officer of the Company, bears interest at the bank’s prime interest rate
      adjusted quarterly (5.25% at June 30, 2008 and 7.75% at December 31, 2007). The
      balance of $100,000 is due in 2012. The Company intends on repaying this note
      during the second half of 2008.





7.  COMMON
      STOCK





For
      the
      six months ended June 30, 2008, 450 ,000
      shares of common stock were issued to a business advisor and consultant to
      the
      Company as part of his compensation package. The shares were valued at $0.23
      per
      share for a total value of $103,500. The Company has a further obligation to
      issue 75,000 shares of common stock per month through August 22,
      2008.





On
      August
      4, 2008 concurrent with the closing of the Master Restructuring Agreement the
      Company increased its authorized common shares to 1.4 billion shares and has
      issued 433,628,275 shares of common stock since June 30, 2008.








F-10




8.  RECLASSIFICATION





We
      reclassified warrants amortization expenses in the three and six month periods
      of 2007 from General and Administrative expenses to interest expense to conform
      to the current period presentation. There is no effect on the net loss for
      the
      prior period.





9.  SUBSEQUENT
      EVENT




On
      July
      10, 2008, the Company, the Company’s wholly-owned subsidiary, Aduromed
      Corporation (“Aduromed”), Pequot Capital Management, Inc. (“Pequot”), on behalf
      of various funds managed by Pequot (the “Pequot Funds”), Sherleigh Associates
      Inc. Defined Benefit Pension Plan (“Sherleigh”), holders of $1,225,000 in
      principal amount of the Company’s 12% Secured
      Promissory Notes due July 31, 2008 (the “Bridge Loan Holders”), and Mr. Joseph
      Esposito, corporate and business development advisor to the Company (“Esposito”)
      entered into a Master Restructuring Agreement (“MRA”) regarding their respective
      investments in the Company.





The
      transactions contempleated by the MRA were consummated as of August 4, 2008
      (the
“Effective time”). As of the Effective time, existing investments in the Company
      will be restructured pursuant to the terms of the MRA and certain other changes
      were implemented The major terms of the MRA are as follows:





Sherleigh
      (i) converted its shares of Series A and Series B Preferred Stock into 20,000,081
      shares of common stock of the Company, par value $0.0001 per share (“Common
      Stock”), (ii) converted accumulated dividends payable on its Preferred Stock as
      of June 30, 2008 in the amount of $383,576 into 15,343,040 shares of Common
      Stock and received additional common stock purchase warrants for 15,343,040
      shares of Common Stock at an exercise price of $0.025 per share, and (iii)
      converted liquidated damages in the amount of $215,000 payable to Sherleigh
      by
      the Company into 8,600,000 shares of Common Stock and received additional common
      stock purchase warrants for 8,600,000 shares of Common Stock at an exercise
      price of $0.025 per share.





The
      Pequot Funds surrendered their shares of Series A and Series B Preferred Stock
      to the Company which shares were cancelled, and the Pequot Funds forfeited
      their
      right to receive accumulated
      dividends payable on their Preferred Stock as of June 30, 2008 in the amount
      of
      $690,436 and liquidated damages in the amount of $387,000 payable to the Pequot
      Funds by the Company.





The
      Series A and B Preferred Warrants were amended such that they collectively
      represent the right to purchase 55,999,998 shares of Common Stock at an exercise
      price of $0.025 per share, of which Pequot Funds holds warrants for the purchase
      of 36,000,001 shares of Common Stock and Sherleigh holds warrants for the
      purchase of 19,999,997 shares of Common Stock and weighted average anti-dilution
      rights have been terminated.





The
      Amended and Restated Stockholders Agreement, dated as of January 23, 2006 among
      the Company, Aduromed, the Pequot Funds and Sherleigh was
      terminated.





The
      Bridge Loan Holders collectively converted a deemed principal amount of
      $1,275,000 of their notes into 93,750,000 shares of Common Stock and all such
      Bridge Loan Holders’ outstanding common stock warrants were collectively
      converted into warrants for the purchase of 93,750,000 shares of Common Stock
      at
      an exercise price of $0.025 per share and anti-dilution rights were terminated. All
      documents entered into in connection with the bridge loan were
      terminated.


F-11






Esposito
      and his new management associates invested $1,250,000 into the Company in return
      for 20,000,000 shares of Common Stock and common stock purchase warrants
      representing an equal amount of shares of Common Stock at an exercise price
      of
      $0.025 per share.





The
      Pequot Funds invested an additional $1,300,000 into the Company, with post
      restructuring holdings of 131,097,456 shares of Common Stock and warrants to
      purchase 131,097,456 shares of Common Stock at $0.025 per share.





Sherleigh
      invested an additional $700,000 into the Company, with post restructuring
      holdings of 71,943,023 shares of Common Stock and warrants to purchase
      71,943,023 shares of Common Stock at $0.025 per share.





F-12





**Item
      2. Management's Discussion and Analysis or Plan of
      Operation**





**Forward
      Looking Statements**





The
      Company is including the following cautionary statement in this Interim Report
      on Form 10-Q for any forward-looking statements made by, or on behalf of, the
      Company including its wholly-owned subsidiary Aduromed Corporation.
      Forward-looking statements include statements concerning plans, objectives,
      goals, strategies, future events or performance and underlying assumptions
      and
      other statements which are other than statements of historical facts. Certain
      statements contained herein are forward-looking statements and accordingly
      involve risks and uncertainties which could cause actual results or outcomes
      to
      differ materially from those expressed in the forward-looking statements. Our
      expectations, beliefs and projections are expressed in good faith and are
      believed by us to have a reasonable basis, including without limitation,
      management’s examination of historical operating trends, data contained in our
      records and other data available from third parties, but there can be no
      assurance that management’s expectation, beliefs or projections will result or
      be achieved or accomplished. In addition to other factors and matters discussed
      elsewhere herein, the following are important factors that, in our view, could
      cause actual results to differ materially from those discussed in the
      forward-looking statements: technological advances by our competitors, changes
      in health care reform, including reimbursement programs, changes to regulatory
      requirements relating to environmental approvals for the treatment of infectious
      medical waste, capital needs to fund any delays or extensions of development
      programs, delays in the manufacture of new and existing products by us or third
      party contractors, market acceptance of our products, the loss of any key
      employees, delays in obtaining federal, state or local regulatory clearance
      for
      new installations and operations, changes in governmental regulations,
      availability of capital on terms satisfactory to us and continuing good
      relations with Aramark Corporation. We are also subject to numerous Risk Factors
      relating to manufacturing, regulatory, financial resources and personnel as
      described in our Annual Report on Form 10-K. We disclaim any obligation to
      update any forward-looking statements to reflect events or circumstances after
      the date hereof.





**Results
      of Operations**





**Three
      Months Ended June 30** **,
      2008 Compared to Three Months Ended June 30, 2007**





*Net
      Revenue*





Total
      revenue for the three months ended June 30, 2008 was $517,955 compared with
      $761,515 for the same three month period in 2007. Revenues derived from the
      sales of our MedClean system decreased by $201,918 while sales and service
      revenues declined by $41,612.





Revenues
      from our MedClean product for the three months ended June 30, 2008 were $330,739
      and $532,657 in the same three month period in 2007. We were unable to
      accelerate installation dates from contracts in backlog currently scheduled
      for
      the fourth quarter of this year into the three months ended June 30, 2008 due
      to
      the clients’ overall construction schedules and no new contracts were awarded in
      the quarter.





Revenues
      derived from the sale of consumables, component parts and service contracts
      decreased by $41,642 or 18% to $187,216 from $228,858 in the same three month
      period of 2007.




*Gross
      Profit*




The
      gross
      profit for the three months ended June 30, 2008 was $184,471 (35.6% of total
      revenue) compared with a gross profit of $352,605 (46.3% of total revenue)
      for
      the same three month period of 2007, Gross profit was impacted by sales volume
      and increased installation costs.




The
      components of costs of revenues for products include direct materials, shipping
      and rigging costs and contract labor primarily used to install, repair and
      maintain our equipment.




*Operating
      Expenses*




3




Total
      operating expenses for the three month period ended June 30, 2008 were $859,249
      compared to $870,339 for the same three month period in 2007, an $11,090
      decrease. The
      addition of a business consultant in August 2007 impacted the quarter by
      $132,598 which was more than off set by savings in all other categories
      amounting to a net $143,688.




*Interest
      (Income) Expense*




Interest
      income for the three months ended June 30, 2008 was $239 compared with $4,840
      of
      interest income in the same three month period of 2007 on reduced cash balances
      available for investment. The Company invests its excess cash in a money market
      account.




Interest
      expense and amortization for the three months ended June 30, 2008 was $836,081
      compared with $47,385 in the same three month period of 2007. Interest expense
      for the three month period ending June 30, 2008 was $52,594 on increased
      borrowings totaling $1,575,000 of principal. In the three month period ending
      June 30, 2008 we recognized non-cash amortization expense for warrants issued
      amounting to $783,487 compared to $41,397 in the same three month period of
      2007. In June of 2007, the Company borrowed $1,275,000 at a rate of 12% per
      annum due on December 27, 2007. The loan was extended and is due on August
      4,
      2008. In consideration of the extension the lenders received 2,450,000 of
      additional warrants which will expire in five years and, have an exercise price
      equal to the exercise price of warrants issued in the Company’s next financing
      involving the issuance of the Company’s common stock or securities convertible
      into such common stock with proceeds of $2,000,000 or more. As additional
      consideration for agreeing to such extension these holders were given the right
      to convert the principal amount of their secured notes into common stock of
      the
      Company prior to the Company’s next Qualified Financing at a conversion price
      equal to one-half of the closing market price of such common stock on the day
      of
      conversion. The beneficial conversion feature was calculated at its intrinsic
      value on December 27, 2007.




*Net
      loss*




Net
      loss
      for the three months ended June 30, 2008 was $(1,510,620) compared to a net
      loss
      for the same three month period in 2007 of $(560,279)




*Net
      Loss Attributable to Common Stockholders*




Net
      loss
      attributable to common stockholders for the three months ended June 30, 2008
      was
      $(1,615,620) or $(0.07) cents per share (basic and diluted), compared to a
      net
      loss of $(665,279) or $(0.03) cents per share (basic and diluted) for the same
      period in 2007.




During
      the quarter, the Company accrued $105,000 in dividends with an interest rate
      of
      6% on $7,000,000, the total value received for both series A and B preferred
      stock.






**Six
      Months Ended June 30, 2008** **Compared
      to Six Months Ended June 30, 2007**





*Net
      Revenue*





Total
      revenue for the six months ended June 30, 2008 was $1,205,981 compared with
      $1,532,121 for the same six month period of 2007. Of the revenue decrease,
      $260,025 was attributable to a decrease of revenues derived from sales of our
      MedClean system and $66,115 was attributable to a decrease of revenues derived
      from the sale of consumables, component parts and service contracts. Contract
      backlog as of June 30, 2008 was $1,737,572.





Revenues
      from our MedClean product for the six months ended June 30, 2007 were $854,223
      and $1,114,248 in the same six month period of 2007. We were unable to
      accelerate installation dates from contracts in backlog originally scheduled
      for
      the fourth quarter of this year into the first half of 2008 due to the clients’
overall construction schedules.





Revenues
      derived from the sale of consumables, component parts and service contracts
      decreased by $66,115 or 15.8% to $351,758 from $417,873 in the same six month
      period of 2007.




4




Orders
      for the MedClean system are contracted by purchase order and are billed in
      3
      increments. Typically, we bill our customers for 25% of the contract value
      at
      signing, 50% when the equipment is shipped to the customer and 25% upon
      completion of installation and start-up. Consumables and component parts are
      billed when shipped and service contracts are invoiced at the start of the
      service period and revenue is pro-rated over the life of the
      contract.




*Gross
      Profit*




The
      gross
      profit for the six months ended June 30, 2008 was $396,899 (32.9% of total
      revenue) compared with a gross profit of $610,258 (39.8% of total revenue)
      for
      the same six month period of 2007, a decrease of $213,359. Gross profit was
      impacted by reduced sales and increased cost.




The
      components of costs of revenues for products include direct materials, shipping
      and rigging costs and contract labor primarily used to install, repair and
      maintain our equipment.




*Operating
      Expenses*




Total
      operating expenses for the six month period ended June 30, 2008 were $1,817,996
      compared with $1,837,611 for the same six month period of 2007, a decrease
      of
      $19,615. The addition of a business consultant in August 2007 impacted the
      six month period by $209,848 and increased legal fees amounting to $42,000
      was
      more than off set by savings in staff reductions and associated costs of
      $263,433. All other categories amounted to a net savings of $8,030.




*Interest
      (Income) Expense*




Interest
      income for the six months ended June 30, 2008 was $614 compared with $13,709
      of
      interest income in the same six month period of 2007 on reduced cash balances
      available for investment. The Company invests its excess cash in a money market
      account. As of June 30, 2008 the interest rate was 0.3%.




Interest
      expense and amortization for the six months ended June 30, 2008 was $1,613,932
      compared with $93,313 in the same six month period of 2008. Interest expense
      for
      the six month period ending June 30, 2008 was $96,106 on increased borrowings
      totaling $1,575,000 of principal. In the six month period ending June 30, 2008
      we recognized non-cash amortization expense for warrants issued amounting to
      $1,517,826 compared to $82,795 in the same six month period of 2008. In June
      of
      2007, the Company borrowed $1,275,000 at a rate of 12% per annum due on December
      27, 2007. The loan was extended and is due on August 4, 2008. In consideration
      of the extension the lenders received 2,450,000 of additional warrants which
      will expire in five years and, have an exercise price equal to the exercise
      price of warrants issued in the Company’s next financing involving the issuance
      of the Company’s common stock or securities convertible into such common stock
      with proceeds of $2,000,000 or more. As additional consideration for agreeing
      to
      such extension these holders were given the right to convert the principal
      amount of their secured notes into common stock of the Company prior to the
      Company’s next Qualified Financing at a conversion price equal to one-half of
      the closing market price of such common stock on the day of conversion. The
      beneficial conversion feature was calculated at its intrinsic value on December
      27, 2007.




*Net
      loss*




Net
      loss
      for the six months ended June 30, 2008 was $(3,034,415) compared to a net loss
      for the same six month period in 2007 of $(1,306,957).




*Net
      Loss Attributable to Common Stockholders*




Net
      loss
      attributable to common stockholders for this period of 2008 was $(3,244,415)
      or
      $(0.15) cents per share (basic and diluted), compared to a net loss of
      $(1,516,957) or $(0.07) cents per share (basic and diluted) for the same period
      in 2006.




During
      the six months ended June 30, 2008 and 2007, the Company accrued $210,000 in
      dividends with an interest rate of 6% on $7,000,000, the total value received
      for both series A and B preferred stock.




Financial
      Condition




5





*Liquidity
      and Capital Resources*





The
      Company’s cash on hand and working capital as of June 30, 2008 and December 31,
      2007 are as follows:





June
                  30,
              
              
              December
                  31,2008
              
              
              2007Cash
                  on hand
              
              $
              71,575
              
              $
              212,215Working
                  capital
              
              $
              (5,647,590
              )
              $
              (2,993,449
              )




The
      Company has purchased no new fixed assets in the first six months of the current
      year. Under current conditions the Company anticipates purchasing approximately
      $50,000 in additional fixed assets in 2008. Net cash used in operating
      activities totaled $438,121 for the six months ended June 30, 2008.





Our
      accounts receivable balance may have dramatic swings from one period to another
      depending upon the timing and the amount of milestone billings included in
      the
      balance at the end of any accounting period. There are three milestone billings
      representing a percentage of the contract value for each installment and our
      payment terms are ``upon receipt''. Receivable balances are typically paid
      within 15 days of the invoice date. Billings for maintenance contracts and
      consumables are due within 45 days and are more numerous but much smaller in
      value than milestone billings. We review our outstanding receivable balances
      on
      a regular basis to ensure that the allowance for bad debt is adequate. Due
      to
      the varying nature in the timing and amounts of the receivable balances as
      noted
      above, the change in the allowance for doubtful account will not necessarily
      correlate with the increase or decrease in the accounts receivable
      balance.


Our
      inventory balance may have dramatic swings from one period to another depending
      upon the expected installation date of our MedClean systems and our accounts
      payable balances can have similar swings depending on payment terms and any
      volume purchases or discounts we may take advantage of from time to time. During
      the six months ended June 30, 2008, the Company reduced its inventory on hand
      by
      $269,840 to $631,098. The accounts payable balance as of June 30, 2008 was
      $826,844.





On
      March
      17, 2008, the Company entered into a factoring agreement with a stockholder
      of
      the Company whereby the Company received $300,000 secured by specific milestone
      billings .The Company agreed to pay interest at 15% per annum. As further
      incentive the Company issued 600,000 warrants with an exercise price of $0.09.
      The warrant agreement expires on March 16, 2013. On May 23, 2008, the Company
      repaid $50,000 of principal on this note and on August 7, 2008 repaid the
      remaining $250,000 plus accrued interest amounting to 16,200.





On
      February 21, 2008, the Company borrowed an additional $50,000 on a $100,000
      line
      of credit it has with a bank. The balance of $100,000 is due in 2012. The
      Company plans on repaying this loan by year end.





On
      August
      4, 2008 the Company closed on a Master Restructuring Agreement (“MRA”) whereby
      the Company has received $4,405,000 in equity funding and has retired or
      converted all of its preferred stock, liquidated damages, accrued dividends
      on
      the preferred stock and a bridge loan in the amount of $1,225,000 into shares
      of
      common stock. Concurrent with the MRA, the Company increased its authorized
      common shares to 1.4 billion shares of common stock.





AII
      has
      an obligation to pay dividends on the value of its preferred stock at a rate
      of
      6%. To date we have accrued $1,074,013 in dividends payable. On August 4, 2008,
      $383,576 was converted into 15,343,040 shares of common stock and warrants
      to
      purchase 15,343,040 shares of common stock at $0.025 per share. The balance
      of
      the accrued dividends was surrendered to the Company.





AII
      has
      accrued $602,000 in liquidated damages payable to its preferred stockholders.
      On
      August 4, 2008, $215,000 was converted into 8,600,000 shares of common stock
      and
      warrants to purchase 8,600,000 shares of common stock at $0.025 per share.
      The
      balance of accrued liquidated damages was surrendered to the Company.





With
      the
      restructuring agreement and $4,405,000 received in cash to date, the Company
      believes it has adequate cash for the next 12 months.





6





**Item
      3. Quantitative and Qualitative Disclosures about Market Risk**





Not
      required ****





**Item
      4. Controls and Procedures**





As
      of the
      six month period ended June 30, 2008 covered by this report, the Company carried
      out, under the supervision and with the participation of the Company's
      management, including its Chief Executive Officer and Chief Financial Officer,
      an evaluation of the effectiveness of the design and operation of the Company's
      disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e)
      under the Securities Exchange Act of 1934). Based upon and as of the date of
      that evaluation, the Chief Executive Officer and Chief Financial Officer
      concluded that the design and operation of these disclosure controls and
      procedures are effective.





There
      has
      been no change in our internal control over financial reporting that occurred
      during the last fiscal quarter that has materially affected, or is reasonably
      likely to materially affect, our internal control over financial
      reporting.




7


**PART
      II--OTHER INFORMATION**





**Item
      1: Legal Proceedings** .





The
      Company has no pending legal proceedings. From time to time, it may be involved
      in various claims, lawsuits or disputes with third parties, and actions
      involving allegations of breach of contract incidental to the normal business
      operations of Aduromed’s business.





**Item
      1A: Risk Factors.**





There
      have been no material changes from the risk factors previously disclosed in
      the
      Company’s Annual Report on Form 10-K for the fiscal year ended December 31,
      2007.





**Item
      2. Unregistered Sales of Equity Securities and Use of
      Proceeds**





Pursuant
      to an agreement dated August 23, 2007, the Company engaged Mr. Joseph Esposito
      as a corporate and business development advisor. During April, May and June
      2008
      the Company issued a total of 225,000 shares of the Company’s common stock to
      Mr. Esposito as part of Mr. Esposito’s compensation package as an advisor to the
      Company. The Company did not receive any cash proceeds from these
      issuances.





The
      offer
      and sale of these securities was claimed exempt from the registration provisions
      of the Securities Act by reason of Section 4(2) thereof and Regulation D
      thereunder. Management made its determination of the availability of such
      exemption based upon the facts and circumstances surrounding the transactions,
      including the representations and warranties made by the investors and the
      fact
      that restrictive legends were placed on the notes and the warrants.





There
      were no other unregistered sales of the Company’s equity securities during the
      quarter ended June 30, 2008.





**Item
      3. Defaults upon Senior Securities.**





There
      has
      been no default in the payment of principal, interest, sinking or purchase
      fund
      installment, or any other material default not cured within 30 days, with
      respect to any indebtedness of the Company exceeding 5 percent of its total
      assets.





**Item
      4. Submission of Matters to a Vote of Security Holders.**





No
      matters have been submitted to security holders of the Company during the period
      covered by this report. ****  ****




**Item
      5: Other Information**





None





8





**I** **tem
      6. Exhibits**











NUMBER
            DESCRIPTION OF EXHIBIT3.1
            Registrant’s
                Certificate of Incorporation (incorporated by reference to Exhibit
                A to
                Appendix I to Registrant’s Proxy Statement on Schedule 14A, filed July 24,
                2000).3.2
            Registrant’s
                Amendment to Certificate of Incorporation, dated December 12, 2005
                (incorporated by reference to Exhibit 3.2 to Registrant’s Form 10-KSB,
                filed April 21, 2006).3.3
            Registrant’s
                Amendment to Certificate of Incorporation, dated January 29, 2007
                (incorporated by reference to Exhibit 3 to Registrant’s Form 8-K, filed
                January 30, 2007).3.4
            Registrant’s
                Amendment to Certificate of Incorporation, dated April 16, 2007
                (incorporated by reference to Exhibit 3 to Registrant’s Form 8-K, filed
                April 16, 2007).3.5
            Registrant’s
                Amendment to Certificate of Incorporation, dated September 26, 2007
                (incorporated by reference to Exhibit 3 to Registrant’s Form 8-K, filed
                September 26, 2007).3.6
            Registrant’s
                Bylaws (incorporated by reference to Registrant's Proxy Statement
                on
                Schedule 14A filed July 14, 2000).4.6
            Form
                of Secured Promissory Note(incorporated
                by reference to Exhibit 4.02 to Registrant’s Form 8-K, filed July 2,
                2007).4.7
            Form
                of Common Stock Purchase Warrant(incorporated
                by reference to Exhibit 4.03 to Registrant’s Form 8-K, filed July 2,
                2007).4.8
            Subsidiary
                Guarantee, dated as of June 27, 2007, from Aduromed Corporation in
                favor
                of the investors named on the signature pages of the Loan and Security
                Agreement(incorporated
                by reference to Exhibit 4.04 to Registrant’s Form 8-K, filed July 2,
                2007).31.1*
            Certification by the Principal Executive Officer
                of
                Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
                (Rule
                13a-14(a) or Rule 15d-14(a)).31.2*
            Certification
              by the
              Principal Financial Officer of Registrant pursuant to Section 302 of
              the
              Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule
              15d-14(a)).32.1*
            Certification
              by the
              Chief Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant
              to
              Section 906 of the Sarbanes-Oxley Act of 2002.32.2*
            Certification
              by the
              Chief Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant
              to
              Section 906 of the Sarbanes-Oxley Act of
              2002.




*
      Filed
      herein.








SIGNATURES





In
      accordance with the requirements of the Exchange Act, the registrant caused
      this
      report to be signed on its behalf by the undersigned, thereunto duly
      authorized.





Registrant





ADUROMED
      INDUSTRIES, INC.





Date:
                  August 14, 2008
              Date:
                  August 14, 2008By:/s/
                  Damien R. Tanaka
              By:/s/
                  Kevin T. DunphyDamien
                  R. Tanaka,
              Kevin
                  T. DunphyPresident
                  and
              Treasurer
                  andChief
                  Executive Officer
              and
                  Chief Financial Officer(Principal
                  Executive Officer)
              (Principal
                  Financial and Accounting Officer)


9